


| | | | | | | | |
|---|----------|----|----------|---|--|---|--|
| INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i> | | | | Docket Number ALT-006US1 (1009/007) | | Application Number 09/779,439 | |
| | | | | Applicant Antoine Noujaim | | | |
| | | | | Filing Date February 8, 2002 | | Group Art Unit 2152 | |
| Sheet | 1 | OF | 1 | | | | |

| U.S. Patent Documents | | | | | | |
|-----------------------|--------------------|------|------|-------|----------|-------------------------------|
| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | NAME | CLASS | SUBCLASS | FILING DATE IF APPROPRIATE |
| | | | | | | |
| | | | | | | |

| Foreign Patent Documents | | | | | | | |
|--------------------------|--------------------|------|---------|-------|----------|-------------|----|
| EXAMINER INITIAL | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUBCLASS | TRANSLATION | |
| | | | | | | YES | NO |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

| Other Documents (Including Author, Title, Date Pertinent Pages, Etc.) | | |
|---|----|--|
| LAB | A1 | Schultz, Birgit C. et al., <i>Cancer Immunol.</i> , "Anti-idiotype therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1)", 46:201-212, 1998. |
| | A2 | Madiyalakan, R. et al., <i>HYBRIDOMA</i> , "Antiidiotype Induction Therapy: Evidence for the Induction of Immune Response Through the Idiotype Network in Patients With Ovarian Cancer After Administration of Anti-CA125 Murine Monoclonal Antibody B43.13", 14:199-203, 1995. |
| | A3 | Reinhartz, S. et al., <i>HYBRIDOMA</i> , "Evaluation of Immunological Responses in Patients with Ovarian Cancer Treated with the Anti-idiotype Vaccine ACA125 by Determination of Intracellular Cytokines—A Preliminary Report", 18:41-45, 1999. |
| | A4 | Schlebusch, Harald, et al., <i>HYBRIDOMA</i> , "A Monoclonal Antiidiotypic Antibody ACA 125 Mimicking the Tumor-Associated Antigen CA 125 for Immunotherapy of Ovarian Cancer", 14:167-174, 1995. |
| | A5 | Kohler, S. et al., <i>Gynakologische Tumoren</i> , "Ammuntherapie des Ovarial-karzinoms mit dem monoklonalen anti-idiotypischen Antikörper ACA 125-Ergebnisse der Phase-ib-Studie", 58:180-186, 1998. |
| | A6 | Leveugle, B. et al., XP-002194280 (#2424), "PSA-directed Immunotherapy of Prostate Cancer". |
| LAB | A7 | Wagner, Uwe A. et al., <i>Biotechnology Therapeutics</i> , "Immunotherapy of Advanced Ovarian Carcinomas by Activation of the idiotypic Network", 3:81-89, 1992. |
| | A8 | |
| | A9 | |
| | B1 | |

| | |
|--|--------------------------------------|
| EXAMINER /Lynn Bristol/ | DATE CONSIDERED 11/05/2006 |
| EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant. | |



| | | | | | |
|--|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/B/PTO | | | | Complete If Known | |
| | | | | Application Number | 10/824554 |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Filing Date | April 14, 2004 |
| | | | | First Named Inventor | Ragupathy Madiyalakan |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 2 | Attorney Docket Number | AREX-P03-005 |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number Number-Kind Code ² (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| LAP | A10 | 4,940,670 | 7/10/90 | Rhodes | |
| | A11 | 4,950,480 | 8/21/90 | Barber et al. | |
| | A12 | 4,997,762 | 3/5/91 | Hanna, Jr. et al. | |
| | A13 | 5,053,224 | 10/1/91 | Koprowski et al. | |
| | A14 | 5,183,657 | 2/2/93 | Buurman | |
| | A15 | 5,308,614 | 5/3/94 | Hakomori | |
| | A16 | 5,194,254 | 3/16/93 | Barber et al. | |
| | A17 | 5,389,530 | 2/14/95 | Hakomori | |
| | A18 | 5,478,556 | 12/26/95 | Elliott et al. | |
| | A19 | 5,500,215 | 3/19/96 | Hakomori | |
| | A20 | 5,009,888 | 4/23/91 | Dunn | |
| | A21 | 5,518,723 | 5/21/96 | Devico et al. | |
| | A22 | 5,013,547 | 5/7/91 | Sweet et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|--|--------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| LAP | B1 | EP 0 153 871 | 9/4/85 | Tse Wen Chang | | |
| | B2 | EP 0288082 | 4/22/88 | Europe | | |
| | B3 | PCT/EP94/01719 | 8/12/94 | PCT | | |
| | B4 | PCT/US90/03142 | STAT | PCT | | |
| | B5 | PCT/US92/11334 | 7/8/93 | PCT | | |
| | B6 | WO 89/01629 | 2/23/89 | PCT | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| LAP | C1 | Abstract of Golumbek et al., Immunologic Research, 1993, pp. 183-192, Vol. 12. | |
| | C2 | Abstract of Hilkens et al., Cancer Letters, 1995, pp. 27-33, Vol. 90. | |
| | C3 | Baum et al., Hybridoma, 1993, pp. 583-589, Vol. 12. | |
| | C4 | Baum et al., Cancer, 1994, pp. 1121-1125, Vol. 73. | |
| | C5 | Chatterjee et al., Cancer Immunol Immunother, 1994, pp. 75-82, Vol. 38. | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Lynn Bristol/ | Date Considered | 11/05/2006 |
|--------------------|----------------|-----------------|------------|




Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 10/824554 |
| | | | | Filing Date | April 14, 2004 |
| | | | | First Named Inventor | Ragupathy Madiyalakan |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 2 | Attorney Docket Number | AREX-P03-005 |

| | | |
|-----|-----|---|
| 400 | C6 | Colman, "Structure of Antibody-Antigen Complexes: Implications for Immune Recognition," Advances in Immunology, 1988, pp. 99-132, Vol. 43. |
| | C7 | Ghiron et al., Photochemistry and Photobiology, 1968, pp. 87-92, Vol. 7. |
| | C8 | Gura, Science, 1997, pp. 1041-1042, Vol. 278. |
| | C9 | Herbert et al., Dictionary of Immunology, Academic Press, London, 1995, pp. 58; 59, 72, 73, and 154. |
| | C10 | Imai et al., Acta Pathol, Japan, 1989, pp. 43-49, Vol. 29. |
| | C11 | Jacobs et al., "Clinical Use of Tumor Markers in Oncology," Current Problems in Cancer, 1991, pp. 299-350. |
| | C12 | Jose et al., Molecular Immunology, 1987, pp. 1145-1150, Vol. 24. |
| | C13 | Kallenbach et al., Curr. Stud Hematol Blood Transfus, 1989, pp. 70-82. |
| | C14 | Kehoe, S., International Journal of Oncology, 1995, pp. 451-458, Vol. 6. |
| | C15 | Kleckowski et al., Photochem. Photobiol., 1962, pp. 299-304, Vol. 1. |
| | C16 | Lanzavecchia, "Mechanisms of antigen uptake for presentation," Current Opinion in Immunology, 1996, pp. 348-354, Vol. 8. |
| | C17 | Lanzavecchia, Science, 1993, pp. 937-944, Vol. 260. |
| | C18 | Leoni et al., Int J Cancer, 1987, pp. 592-597, Vol. 40. |
| | C19 | Madiyalakan et al., "OVAREX™ MAb-B43.13:IFN-γ Could Improve the Ovarian Tumor Cell Sensitivity to CA125-Specific Allogenic Cytotoxic T Cells," Hybridoma, 1997, pp. 41-45, Vol. 16. |
| | C20 | Madiyalakan et al., Hybridoma, 1995, pp. 199-203, Vol. 14. |
| | C21 | Murray et al., J.A.M.A., 1955, pp. 8-14. |
| | C22 | Nemazee et al., PNAS, 1982, pp. 3828-3832, Vol. 79. |
| | C23 | Noujaim et al., Current Tumor Diagnosis, 1994, pp. 823-829. |
| | C24 | Prodouz et al., Blood, 1987, pp. 589-592, Vol. 70. |
| | C25 | Simitsek et al., "Modulation of Antigen Processing by Bound Antibodies Can Boost or Suppress Class II Major Histocompatibility Complex Presentation of Different T Cell Determinants," Journal of Experimental Medicine, 1995, pp. 1957-1963, Vol. 181. |
| | C26 | Stevenson et al., Immunol, 1994, pp. 16-19, Vol. 2. |
| | C27 | Sykes et al., The Journal of Nuclear Medicine, 1995, pp. 1913-1922, Vol. 36. |
| ↓ | C28 | Thomson et al., Clin Exp Immunol, 1994, pp. 351-357, Vol. 98. |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Lynn Bristol/ | Date Considered | 11/05/2006 |
|--------------------|----------------|-----------------|------------|



| | | | |
|---|------------------------|--------------------------|-----------------------|
| Substitute for Form 1449A/B/PTO | | Complete If Known | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | Application Number | 10/824,554 |
| | | Filing Date | April 14, 2004 |
| | | First Named Inventor | Ragupathy Madiyalakan |
| | | Art Unit | 1641 |
| | | Examiner Name | Not Yet Assigned |
| Sheet 1 of 1 | Attorney Docket Number | AREX-P03-005 | |


| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| LAP | A23 | 5,240,833 | Aug. 31, 1993 | Nudelman et al. | |
| | A24 | 5,807,978 | Sept. 15, 1998 | Kokolus et al. | |
| | A25 | 6,088,613 | July 11, 2000 | Unger | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | MM-DD-YYYY | | | |
| LAP | B7 | EP 315,456 | 05-1989 | Fagani | | |
| | | | | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | | | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Lynn Bristol/ | Date Considered | 11/05/2006 |
|--------------------|----------------|-----------------|------------|



SPTO/SB/08a/b (07-05)

Approved for use through 07/31/2008. OMB 0851-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/B/PTO | | | | Complete if Known | |
| SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Application Number | 10/824,554 |
| | | | | Filing Date | April 14, 2004 |
| | | | | First Named Inventor | Ragupathy Madiyalakan |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 1 | of | 3 | Attorney Docket Number | AREX-P03-005 |

| U.S. PATENT DOCUMENTS | | | | | | |
|-----------------------|-----------------------|--|--|-----------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | | |
| LAB | AA | US-4,740,371 | | 04-26-1988 | St. Remy et al. | |
| | AB | US-4,879,225 | | 11-07-1989 | Morgan Jr. et al. | |
| | AC | US-5,512,283 | | 04-30-1996 | Byers et al. | |
| | AD | US-5,532,159 | | 07-02-1996 | Webb et al. | |
| | AE | US-5,583,202 | | 12-10-1996 | Zanetti | |
| | AF | US-5,591,593 | | 01-07-1997 | Courtenay-Luck | |
| | AG | US-5,652,114 | | 07-29-1997 | Chu et al. | |
| | AH | US-5,688,657 | | 11-18-1997 | Tsang et al. | |
| | AI | US-5,725,856 | | 03-10-1998 | Hudziak et al. | |
| | AJ | US-5,869,445 | | 02-09-1999 | Cheever et al. | |
| | AK | US-5,997,315 | | 11-02-1999 | Chatterjee et al. | |
| | AL | US-6,068,830 | | 05-30-2000 | Diamandis et al. | |
| | AM | US-6,077,519 | | 06-20-2000 | Storkus et al. | |
| | AN | US-6,140,091 | | 10-31-2000 | Raso et al. | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|-----------------------|---|--------------------------------|---|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| LAB | BA | WO 93/20185 | 10-14-1993 | Steinman et al. | | |
| | BB | WO 94/21287 | 09-29-1994 | Berzofsky et al. | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| LAB | CA | Algarra et al., "Altered MHC class I antigens in tumors", Int. J. of Clin. & Lab, 27:95-102 (1997). | |
| | CB | Antonia et al., "Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein", Int. Imm., 7:715-725 (1995). | |
| | CC | Bachmann et al., "Regulation of IgG antibody titers by the amount persisting of immune-complexed antigen," Eur. J. Imm., 24:2567-70 (1994). | |
| | CD | Baum et al., "Activating Anti-Idiotypic Human Anti-Mouse Antibodies for Immunotherapy of Ovarian Carcinoma", Cancer, 73:1121-25 (1994). | |
| | CE | Benichou et al., "Disruption of the determinant hierarchy on a self-MHC peptide: concomitant tolerance induction to the dominant determinant and priming to the cryptic self-determinant", Int. Imm., 6:131-38 (1994). | |
| | CF | Bodey et al., "Failure of Cancer Vaccines: The Significant Limitations of this Approach to Immunotherapy", Anticancer Res., 20:2665-2676 (2000). | |
| | CG | Chattopadhyay et al., "Human high molecular weight-melanoma associated antigen mimicry | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Lynn Bristol/ | Date Considered | 11/05/2006 |
|--------------------|----------------|-----------------|------------|

3190902

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/824,554 |
| | | | | Filing Date | April 14, 2004 |
| | | | | First Named Inventor | Ragupathy Madiyalakan |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 2 | of | 3 | Attorney Docket Number | AREX-P03-005 |

| | | | |
|-----|-----|---|--|
| LAA | | by an anti-idiotypic antibody: characterization of the immunogenicity and the immune response to the mouse monoclonal antibody IMel-1," Cancer Res., 5:6045-51 (1991). | |
| | CH | Cibotti, PNAS, "Tolerance to a self-protein involves its immunodominant but does not involve its subdominant determinants", 89:416-20 (1992). | |
| | CI | Clark, "Protein Engineering of antibody Molecules for Prophylactic and therapeutic Applications in Man, (monograph), Prot. Eng., 1 (1993). | |
| | CJ | Crowley et al., "Dendritic cells are the principal cells in mouse spleen bearing immunogenic fragments of foreign proteins", J. Exp. Med., 172:383-386 (1990). | |
| | CK | De la Salle, "FcyR on Human Dendritic Cells", Human IgG Receptors, p. 39-55 (1996). | |
| LAA | CL | Fagerberg, "Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A," Cancer Imm., 12:81-87 (1996). | |
| | CM | Frodin et al., Hybridoma, "Induction of anti-idiotypic (ab2) and anti-anti-idiotypic (ab3) antibodies in patients treated with the mouse monoclonal antibody 17-1A (ab1). Relation to the clinical outcome--an important antitumoral effector function?," 10:421-31 (1991). | |
| | CN | Goldenberg et al., "Cancer Diagnosis and Therapy with Radiolabeled Antibodies", In: Immunoconjugates, Antibody Conjugates in Radioimaging and Therapy of Cancer, Vogel. Ed., 259-280 (1987). | |
| | CO | Jumic-Winkler, "Clinical evaluation of a new prostate-specific antigen sandwich ELISA which employs four monoclonal antibodies directed at different epitopes of prostate-specific antigen", Eur. Urol., 24:487-91 (1993). | |
| | CP | Keder et al., "Cancer Immunotherapy: Are the results discouraging? Can they be improved?", Adv. Cancer Res., 59:245-323 (1992). | |
| | CQ | Klaus, "Antigen-antibody complexes elicit anti-idiotypic antibodies to self-idiotopes," Nature, 272:265-66 (1978). | |
| | CR | Lee et al., "Increased Vaccine-Specific T Cell Frequency After Peptide-Based Vaccination Correlates with Increased Susceptibility to In Vitro Stimulation But Does Not Lead to Tumor Regression", J. Imm., 163:6292-300 (1999). | |
| | CS | Leitzel, "Elevated Soluble c-erbB-2 Antigen Levels in the Serum and Effusions of a Proportion of Breast Cancer Patients", J. Clin. Oncol., 10:1436-1442 (1992). | |
| | CT | McGuckin et al., "Circulating tumour-associated mucin concentrations, determined by the CASA assay, in healthy women," Clin. Chim. Acta, 214:139-51 (1993). | |
| | CU | Nishimura, "The critical role of TH1-dominant immunity in tumor immunology, Cancer Chemother", Cancer/Chemo, 46:S52-S61 (2000). | |
| | CV | Ohlen et al., "Expression of a Tolerizing Tumor Antigen in Peripheral Tissue Does Not Preclude Recovery of High-Affinity CB ^{HT} Cells of CTL Immunotherapy of Tumors Expressing the Antigen", J. Imm., 166:2863-2870 (2001). | |
| | CW | Pani et al., "Failure of presented, nondominant self epitope to induce tolerance - implications for autoimmune-diseases", Imm. Inv., 23:337-346 (1994). | |
| | CX | Paul, "Factors limiting effective tumor immunity", Fund. Imm., 1163-69 (1993). | |
| | CY | Rooijen, "The role of the FDC-retained immune complex network and its dynamics in the activity of germinal centres," Res. Immunol., 144:545-52 (1993). | |
| | CZ | Sallusto, "Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α ", J. Exp. Med., 179:1109-1118 (1994). | |
| | CA1 | Schlom, In: Molecular foundations of Oncology, S. Broder, Ed., Mol. Fndns. Oncol., 105-107 (1991). | |
| | CB1 | Schwartz, "Cancer Markers," In: Cancer: Principles and Practice of Clinical Oncology, 4 th Ed., 531-542 (1994). | |
| | CC1 | Semino et al., "Heterogeneity of the alpha-interferon-mediated overexpression of class-I and class-II major histocompatibility complex molecules in primary cultured cancer cells", J. Biol. Regs., 7:99-105 (1993). | |

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Lynn Bristol/ | Date Considered | 11/05/2006 |
|--------------------|----------------|-----------------|------------|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|-----------------------|
| Substitute for form 1449A/B/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete If Known | |
| | | | | Application Number | 10/824,554 |
| | | | | Filing Date | April 14, 2004 |
| | | | | First Named Inventor | Ragupathy Madiyalakan |
| | | | | Art Unit | 1641 |
| | | | | Examiner Name | Not Yet Assigned |
| Sheet | 3 | of | 3 | Attorney Docket Number | AREX-P03-005 |

| | | | |
|-----|-----|---|--|
| LAB | CD1 | Tassi et al., "Immunogenicity of anti-idiotypic antibodies and of their F(ab') ₂ fragments," Imm. Letts., 27:39-44 (1991). | |
| | CE1 | Vrba et al., "Carcinoembryonic antigen: evidence for multiple antigenic determinants and isoantigens", PNAS, 72:4602-06 (1975). | |
| | CF1 | Ward, "Unconjugated antibodies for cancer therapy: lessons from the clinic" Cancer Treatment Rev., 23:305-319 (1997). | |
| | CG1 | Watts et al., "Suppressive Effect of Antibody on Processing of T Cell Epitopes", J. Exp. Med., 178:1459-1463 (1993). | |
| | CH1 | Yin et al., "Serological and immunochemical analysis of Lewis y (Ley) blood group antigen expression in epithelial ovarian cancer," Int. J. Cancer, 65-406-412 (1996). | |
| ↓ | CI1 | Qi et al., "Induction of idiotypic network to anti-MUC-1 antibody in breast cancer", Proceedings of the American Association for Cancer Research Annual, 39:367 (1998). | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|--------------------|----------------|-----------------|------------|
| Examiner Signature | /Lynn Bristol/ | Date Considered | 11/05/2006 |
|--------------------|----------------|-----------------|------------|